Vaccine Breakthrough Infections with SARS-CoV-2 Variants

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology

Rambaut, A., Holmes, E. C., O’Toole, Á., Hill, V., McCrone, J. T., Ruis, C., du Plessis, L., & Pybus, O. G. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0770-5 · Cited by 2,543

Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals

Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853

Evolution of antibody immunity to SARS-CoV-2

Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Wang, Z., Schmidt, F., Weisblum, Y., Muecksch, F., Barnes, C. O., Finkin, S., Schaefer-Babajew, D., Cipolla, M., Gaebler, C., Lieberman, J. A., et al. (2021) · Nature · doi:10.1038/s41586-021-03324-6 · Cited by 1,343

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Weisblum, Y., Schmidt, F., Zhang, F., DaSilva, J., Poston, D., Lorenzi, J. C., Muecksch, F., Rutkowska, M., Hoffmann, H.-H., Michailidis, E., et al. (2020) · eLife · doi:10.7554/elife.61312 · Cited by 1,308

SARS-CoV-2 evolution during treatment of chronic infection

Kemp, S. A., Collier, D. A., Datir, R. P., Ferreira, I. A. T. M., Gayed, S., Jahun, A., Hosmillo, M., Rees-Spear, C., Mlcochova, P., Lumb, I. U., et al. (2021) · Nature · doi:10.1038/s41586-021-03291-y · Cited by 1,097

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Planas, D., Bruel, T., Grzelak, L., Guivel-Benhassine, F., Staropoli, I., Porrot, F., Planchais, C., Buchrieser, J., Rajah, M. M., Bishop, E., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01318-5 · Cited by 697

Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric virusesPreprint

Schmidt, F., Weisblum, Y., Muecksch, F., Hoffmann, H., Michailidis, E., Lorenzi, J. C. C., Mendoza, P., Rutkowska, M., Bednarski, E., Gaebler, C., et al. (2020) · bioRxiv · doi:10.1101/2020.06.08.140871 · Cited by 600

Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses

Schmidt, F., Weisblum, Y., Muecksch, F., Hoffmann, H.-H., Michailidis, E., Lorenzi, J. C. C., Mendoza, P., Rutkowska, M., Bednarski, E., Gaebler, C., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20201181 · Cited by 572

mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

Stamatatos, L., Czartoski, J., Wan, Y.-H., Homad, L. J., Rubin, V., Glantz, H., Neradilek, M., Seydoux, E., Jennewein, M. F., MacCamy, A. J., et al. (2021) · Science · doi:10.1126/science.abg9175 · Cited by 557

Interleukin-1 Inhibitors and Vaccination Including COVID-19 in Inflammatory Rheumatic Diseases: A Nonsystematic Review

Atagündüz, P., Keser, G., & Soy, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.734279 · Cited by 14

High viral loads: what drives fatal cases of COVID-19 in vaccinees? – an autopsy study

Hirschbühl, K., Schaller, T., Märkl, B., Claus, R., Sipos, É., Rentschler, L., Maccagno, A., Grosser, B., Kling, E., Neidig, M., et al. (2022) · Modern Pathology · doi:10.1038/s41379-022-01069-9 · Cited by 12

Kinetics of neutralizing antibodies against SARS-CoV-2 infection according to sex, age, and disease severity

Kim, Y., Bae, J., Kwon, K. T., Chang, H., Lee, W. K., Park, H., Kim, J., Choi, I., Park, M., & Kim, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-17605-1 · Cited by 12

SARS-CoV-2 breakthrough infections during the second wave of COVID-19 at Pune, India

Doke, P. P., Mhaske, S. T., Oka, G. A., Kulkarni, R., Muley, V., Mishra, A. C., & Arankalle, V. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1040012 · Cited by 12

A highly sensitive nanobody-based immunoassay detecting SARS-CoV-2 nucleocapsid protein using all-recombinant reagents

Santos, P. S.-D. L., Padula-Roca, C., Simon, X., Echaides, C., Lassabe, G., & González‐Sapienza, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1220477 · Cited by 12

Dynamics of SARS-CoV-2 variants of concern (VOC) in Bangladesh during the first half of 2021

Afrin, S. Z., Islam, M. T., Paul, S. K., Kobayashi, N., & Parvin, R. (2021) · Virology · doi:10.1016/j.virol.2021.10.005 · Cited by 13

High failure rate of ChAdOx1-nCoV19 immunization against asymptomatic infection in healthcare workers during a Delta variant surge

Ujjainiya, R., Tyagi, A., Sardana, V., Naushin, S., Bhatheja, N., Kumar, K., Barman, J., Prakash, S., Kutum, R., Bhaskar, A. K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29404-3 · Cited by 10

Breakthrough SARS-CoV-2 infections after vaccination: a critical review

Afshar, Z. M., Barary, M., Hosseinzadeh, R., Alijanpour, A., Hosseinzadeh, D., Ebrahimpour, S., Nazary, K., Sio, T. T. W., Sullman, M. J. M., Carson‐Chahhoud, K., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2051412 · Cited by 14

Neddylation tunes peripheral blood mononuclear cells immune response in COVID-19 patients

Serrano‐Maciá, M., Lachiondo‐Ortega, S., Iruzubieta, P., Goikoetxea‐Usandizaga, N., Bosch, A., Egia‐Mendikute, L., Jiménez-Lasheras, B., Azkargorta, M., Elortza, F., Martinez-Redondo, D., et al. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01115-0 · Cited by 11

A systematic review of current status and challenges of vaccinating children against SARS-CoV-2

Zhang, M., Zhang, P., Liang, Y., Du, B., Li, L., Yu, Z., Wang, H., Wang, Q., Zhang, X., & Zhang, W. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.10.006 · Cited by 11

Dynamics of Antibody and T Cell Immunity against SARS-CoV-2 Variants of Concern and the Impact of Booster Vaccinations in Previously Infected and Infection-Naïve Individuals

Faas, M. R., Mak, W. A., Markus, H. Y., van der Zwan, E. M., van der Vliet, M., Koeleman, J. G. M., & Ong, D. S. Y. (2022) · Vaccines · doi:10.3390/vaccines10122132 · Cited by 11

Coronavirus disease 2019 (COVID-19) mRNA vaccine effectiveness in asymptomatic healthcare workers

Knobel, P., Serra, C., Grau, S., Ibañez, R., Díaz, P., Ferrández, O., Villar, R., Lopez, A. F., Fulquet, N. P., Horcajada, J. P., et al. (2021) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2021.287 · Cited by 11

Booster or additional vaccination doses in patients vaccinated against COVID-19

Botella, A. G., García‐Lledó, A., Gómez‐Pavón, J., del Castillo, J. M. G., Hernández‐Sampelayo, T., Delgado, M. C. M., Martín‐Sánchez, F. J., Martínez‐Sellés, M., Molero, J., Guillén, S. M., et al. (2021) · Revista Española de Quimioterapia · doi:10.37201/req/149.2021 · Cited by 14

A Promising Vaccination Strategy against COVID-19 on the Horizon: Heterologous Immunization

Mattoo, S.-U.-S., & Myoung, J. (2021) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2111.11026 · Cited by 11

Incidence and severity of COVID-19 infection post-vaccination: a survey among Indian doctors

Parameswaran, A., Apsingi, S., Eachempati, K. K., Dannana, C. S., Jagathkar, G. M., Iyer, M., & Aribandi, H. (2022) · Infection · doi:10.1007/s15010-022-01758-2 · Cited by 13

Factors Associated with Change in SARS-CoV-2 Antibody Titers from Three to Six Months after the Administration of the BNT162b2 mRNA COVID-19 Vaccine among Healthcare Workers in Japan: A Prospective Study

Mochizuki, T., Hori, T., Yano, K., Ikari, K., & Okazaki, K. (2022) · Internal Medicine · doi:10.2169/internalmedicine.8902-21 · Cited by 11

Breakthrough cases of Omicron and Delta variants of SARS-CoV-2 during the fifth wave in Pakistan

Jamal, Z., Haider, M., Ikram, A., Salman, M., Rana, M. S., Rehman, Z., Haider, S. A., Ammar, M., Nisar, N., & Umair, M. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.987452 · Cited by 10

SARS-CoV-2 intra-host single-nucleotide variants associated with disease severity

Zhang, Y., Jiang, N., Qi, W., Li, T., Zhang, Y., Wu, J., Zhang, H., Zhou, M., Cui, P., Yu, T., et al. (2022) · Virus Evolution · doi:10.1093/ve/veac106 · Cited by 11

Deep Learning Analysis of COVID-19 Vaccine Hesitancy and Confidence Expressed on Twitter in 6 High-Income Countries: Longitudinal Observational Study

Zhou, X., Song, S., Zhang, Y., & Hou, Z. (2023) · Journal of Medical Internet Research · doi:10.2196/49753 · Cited by 16

What is always necessary throughout efforts to prevent and control COVID-19 and other infectious diseases? A physical containment strategy and public mobilization and management

Luo, M., Sun, J., Gong, Z., & Wang, Z. (2021) · BioScience Trends · doi:10.5582/bst.2021.01218 · Cited by 11

B cell receptor signatures associated with strong and poor SARS-CoV-2 vaccine responses

Lin, K., Zhou, Y., Ai, J., Wang, Y. A., Zhang, S., Qiu, C., Lian, C., Gao, B., Liu, T., Wang, H., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2030197 · Cited by 11

Early reduction of SARS-CoV-2-replication in bronchial epithelium by kinin B2 receptor antagonism

Jakwerth, C. A., Feuerherd, M., Guerth, F. M., Oelsner, M., Schellhammer, L., Giglberger, J., Pechtold, L., Jerin, C., Kugler, L. M., Mogler, C., et al. (2022) · Journal of Molecular Medicine · doi:10.1007/s00109-022-02182-7 · Cited by 12

COVID-19 vaccination challenges: A mini-review

Afshar, Z. M., Barary, M., Hosseinzadeh, R., Karim, B., Ebrahimpour, S., Nazary, K., Sio, T. T. W., Sullman, M. J. M., Carson‐Chahhoud, K., Moudi, E., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2066425 · Cited by 14

Designing an integrated sustainable-resilient mix-and-match vaccine supply chain network

Jahed, A., Molana, S. M. H., Tavakkoli-Moghaddam, R. R., & Valizadeh, V. (2024) · Annals of Operations Research · doi:10.1007/s10479-024-06211-1 · Cited by 12

Rapid and accurate identification of SARS-CoV-2 variants containing E484 mutation

Zhang, Y., Wei, Y., Yang, S., Li, Y., Wang, J., Nie, Z., Bi, Y., Liu, W., Wang, L., & Yang, L. (2021) · The Innovation · doi:10.1016/j.xinn.2021.100183 · Cited by 10

Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2

Saunders, N., Planas, D., Bolland, W., Rodriguez, C., Fourati, S., Buchrieser, J., Planchais, C., Prot, M., Staropoli, I., Guivel‐Benhassine, F., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103934 · Cited by 13

Sequencing during Times of Change: Evaluating SARS-CoV-2 Clinical Samples during the Transition from the Delta to Omicron Wave

Feng, S., Ali, M. S., Evdokimova, M., Reid, G., Clark, N. M., Uprichard, S. L., & Baker, S. C. (2022) · Viruses · doi:10.3390/v14071408 · Cited by 9

COVID-19 pandemic: ethical issues and recommendations for emergency triage

Wu, L., & Kong, X. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1160769 · Cited by 10

Effect of surgical mask on exercise capacity in COPD: a randomised crossover trial

Hirai, K., Tanaka, A., Sato, H., Sato, Y., Uchida, Y., Inoue, E., & Sagara, H. (2021) · European Respiratory Journal · doi:10.1183/13993003.02041-2021 · Cited by 10

Higher vaccination rates predict reduction in SARS-CoV-2 transmission across the United States

Au, J. (2022) · Infection · doi:10.1007/s15010-022-01802-1 · Cited by 10

COVID-19 Vaccination Strategies and Their Adaptation to the Emergence of SARS-CoV-2 Variants

Stefanelli, P., & Rezza, G. (2022) · Vaccines · doi:10.3390/vaccines10060905 · Cited by 10

Enhancement of SARS-CoV-2 N Antigen-Specific T Cell Functionality by Modulating the Autophagy-Mediated Signal Pathway in Mice

Wen, Z., Yuan, Y., Zhao, Y., Wang, H., Han, Z., Li, M., Yuan, J., & Sun, C. (2023) · Viruses · doi:10.3390/v15061316 · Cited by 10

Breakthrough infection after COVID-19 vaccination: A threat for Nepal due to SARS-CoV-2 variants circulating in 2nd wave ravaging India

Shah, J. N., Samson, P., Pradhan, N. M. S., Maharjan, S., Shrestha, A., Shah, J., Shah, J., & Sarala, K. C. (2021) · Journal of Patan Academy of Health Sciences · doi:10.3126/jpahs.v8i2.37287 · Cited by 9

Design, immunogenicity and efficacy of a Pan-SARS-CoV-2 synthetic DNA vaccinePreprint

Reed, C. C., Schultheis, K., Andrade, V. M., Kalia, R., Tur, J., Schouest, B., Elwood, D., Walters, J. N., Maricic, I., Doan, A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.11.443592 · Cited by 10

Breakthrough COVID-19 case after full-dose administration of CoronaVac vaccine

Ulhaq, Z. S., Soraya, G. V., & Indriana, K. (2021) · Indian Journal of Medical Microbiology · doi:10.1016/j.ijmmb.2021.05.017 · Cited by 10

SARS-CoV-2 Mutations Responsible for Immune Evasion Leading to Breakthrough Infection

Sahni, C., Chowdhury, P. B. R., Devadas, D., Ashish, A., Singh, N. K., Yadav, A. K., Kaur, M., Mishra, S., Vishwakarma, S., & Singh, R. (2022) · Cureus · doi:10.7759/cureus.29544 · Cited by 9

Clinical development of antivirals against SARS-CoV-2 and its variants

Lan, Q., Yan, Y., Zhang, G., Xia, S., Zhou, J., Lu, L., & Jiang, S. (2023) · Current Research in Microbial Sciences · doi:10.1016/j.crmicr.2023.100208 · Cited by 9

Longitudinal effects of SARS-CoV-2 breakthrough infection on imprinting of neutralizing antibody responses

Einhauser, S., Asam, C., Weps, M., Senninger, A., Peterhoff, D., Bauernfeind, S., Asbach, B., Carnell, G., Heeney, J. L., Wytopil, M., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105438 · Cited by 8

Nationwide Seroprevalence of SARS-CoV-2 IgG Antibodies among Four Groups of Primary Health-Care Workers and Their Household Contacts 6 Months after the Initiation of the COVID-19 Vaccination Campaign in France: SeroPRIM Study Protocol

Pouquet, M., Decarreaux, D., Prévot-Monsacre, P., Hervé, C., Werner, A., Grosgogeat, B., Blanché, H., Rabiéga, P., Laupie, J., Kochert, F., et al. (2021) · Pathogens · doi:10.3390/pathogens10070911 · Cited by 9

Virological and Serological Characterisation of SARS-CoV-2 Infections Diagnosed After mRNA BNT162b2 Vaccination Between December 2020 and March 2021

Colavita, F., Meschi, S., Gruber, C. E. M., Rueca, M., Vairo, F., Matusali, G., Lapa, D., Giombini, E., Carli, G. D., Spaziante, M., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.815870 · Cited by 9

Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease

Deschambault, Y., Lynch, J., Warner, B. M., Tierney, K. J., Huynh, D., Vendramelli, R., Tailor, N., Frost, K. L., Sajesh, B. V., LeBlanc, K., et al. (2022) · Journal of Virology · doi:10.1128/jvi.00389-22 · Cited by 9

A SARS-CoV-2 outbreak associated with vaccine breakthrough in an acute care hospital

Park, S. Y., Kim, T. H., Lee, E. J., Loeb, M. B., Jeong, Y. S., Kim, J. H., Oh, S. M., Cheong, S., Park, H., Jo, S., et al. (2022) · American Journal of Infection Control · doi:10.1016/j.ajic.2022.05.010 · Cited by 9

COVID-19: Clinical features and outcomes in unvaccinated 2-dose and 3-dose vaccinated against SARS-CoV-2 patients with systemic autoimmune and autoinflammatory rheumatic diseases

Bakasis, A., Mavragani, C. P., Voulgari, P. V., Gerolymatou, N., Argyropoulou, O. D., Vlachoyiannopoulos, P. G., Skopouli, F. N., Tzioufas, A. G., & Moutsopoulos, H. Μ. (2022) · Journal of Autoimmunity · doi:10.1016/j.jaut.2022.102846 · Cited by 9

High Incidence of SARS-CoV-2 Variant of Concern Breakthrough Infections Despite Residual Humoral and Cellular Immunity Induced by BNT162b2 Vaccination in Healthcare Workers: A Long-Term Follow-Up Study in Belgium

Calcoen, B., Callewaert, N., Vandenbulcke, A., Kerstens, W., Imbrechts, M., Vercruysse, T., Dallmeier, K., Weyenbergh, J. V., Maes, P., Bossuyt, X., et al. (2022) · Viruses · doi:10.3390/v14061257 · Cited by 8

High seroprevalence of Immunoglobulin G (IgG) and IgM antibodies to SARS-CoV-2 in asymptomatic and symptomatic individuals amidst vaccination roll-out in western Kenya

Awandu, S. S., Ochieng, A. O., Onyango, B., Magwanga, R. O., Were, P., Ochung’, A. A., Okumu, F. O., Oloo, M. A., Katieno, J. S., Lidechi, S., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0272751 · Cited by 9

Nirmatrelvir/Ritonavir Use and Hospitalizations or Death in a Previously Uninfected Nonhospitalized High-Risk Population With COVID-19: A Matched Cohort Study

Butt, A. A., Peng, Y., Shaikh, O. S., Talisa, V. B., Omer, S. B., & Mayr, F. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad393 · Cited by 9

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in vaccinated and unvaccinated healthcare personnel in a Veterans’ Affairs healthcare system

Redmond, S. N., Jones, L. D., Sadri, N., Schmotzer, C. L., Navas, M. E., Zabarsky, T. F., Bhullar, D., & Donskey, C. J. (2021) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2021.256 · Cited by 9

Increased Antibody Avidity and Cross-Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Variants by Hyperimmunized Transchromosomic Bovine–Derived Human Immunoglobulins for Treatment of Coronavirus Disease 2019

Tang, J., Grubbs, G., Lee, Y., Wu, H., Luke, T. C., Egland, K. A., Bausch, C. L., Sullivan, E. J., & Khurana, S. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac031 · Cited by 9

Assessment of BIV1-CovIran inactivated vaccine–elicited neutralizing antibody against the emerging SARS-CoV-2 variants of concern

Salehi, M., Hosseini, H., Jamshidi, H., Jalili, H., Tabarsi, P., Mohraz, M., Karimi, H., Lotfinia, M., Aalizadeh, R., Mohammadi, M., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.02.030 · Cited by 9

Resilience of Spike-Specific Immunity Induced by COVID-19 Vaccines against SARS-CoV-2 Variants

Ballesteros-Sanabria, L., Pelaez-Prestel, H. F., Ras-Carmona, A., & Reche, P. A. (2022) · Biomedicines · doi:10.3390/biomedicines10050996 · Cited by 9

Large-Scale SARS-CoV-2 Antigen Testing With Real-World Specimens

Parikh, A., Cooper, L. A., Frogel, D., LeBenger, K., Cooper, C. K., & Parvu, V. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.836328 · Cited by 9

Modeling the Influence of Vaccine Administration on COVID-19 Testing Strategies

Forde, J. E., & Ciupe, S. M. (2021) · Viruses · doi:10.3390/v13122546 · Cited by 9

Cost-effectiveness analysis of statins for the treatment of hospitalized COVID-19 patients

Chow, R., Simone, C. B., Prsic, E. H., & Shin, H. J. (2022) · Annals of Palliative Medicine · doi:10.21037/apm-21-2797 · Cited by 9

Activity of a Carbohydrate-Binding Module Therapy, Neumifil, against SARS-CoV-2 Disease in a Hamster Model of Infection

Fell, R., Potter, J. A., Yuille, S., Salguero, F. J., Watson, R., Ngabo, D., Gooch, K. E., Hewson, R., Howat, D., & Dowall, S. (2022) · Viruses · doi:10.3390/v14050976 · Cited by 9

Ultra-Long-Acting Antivirals as Chemical Vaccines to Prevent Viral Diseases

Soriano, V., Edagwa, B., de Mendoza, C., Barreiro, P., Corral, O. J., Treviño, A., & Gendelman, H. E. (2022) · Future Microbiology · doi:10.2217/fmb-2021-0254 · Cited by 9

Adverse events following immunization with ChAdOx1 nCoV-19 and BBIBP-CorV vaccine: A comparative study among healthcare professionals of Nepal

Rayamajhi, S., Rafi, M. A., Tripathi, N., Dongol, A. S., Pandey, M., Rayamajhi, S., Bhandari, S., Shrestha, P., Hasan, M. T., & Hossain, M. G. (2022) · PLoS ONE · doi:10.1371/journal.pone.0272729 · Cited by 10

Reduced neutralization of SARS-CoV-2 B.1.617 variant by inactivated and RBD-subunit vaccinePreprint

Hu, J., Wei, X., Jin, X., Peng, P., Xu, F.-L., Wu, K., Luo, F., Jin, A., Fang, L., Liu, B., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.09.451732 · Cited by 9

SARS-CoV-2 vaccine breakthrough infection following a previous infection in a healthcare worker

Gupta, A., Bhoyar, R. C., MIRZA, S. B., Jolly, B., Senthivel, V., Shamnath, A., Divakar, M. K., Imran, M., Gupta, V., Agrawal, S. J., et al. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.10.008 · Cited by 9

Mucosal Adenoviral-vectored Vaccine Boosting Durably Prevents XBB.1.16 Infection in Nonhuman PrimatesPreprint

Gagné, M., Flynn, B. J., Andrew, S. F., Flebbe, D. R., Mychalowych, A., Lamb, E., Davis-Gardner, M. E., Burnett, M. R., Serebryannyy, L., Lin, B. C., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.06.565765 · Cited by 9

Glycoprotein molecular dynamics analysis: SARS-CoV-2 spike glycoprotein case study

Coutinho, J. V. P., Macedo-da-Silva, J., Mule, S. N., Kronenberger, T., Rosa-Fernandes, L., Wrenger, C., & Palmisano, G. (2022) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2022.05.004 · Cited by 8

The rates and symptoms of natural and breakthrough infection pre- and post- Covid-19 non-mRNA vaccination at various peaks amongst Iranian healthcare workers

Jamalidoust, M., Eilami, O., Ashkan, Z., Ziyaeyan, M., Aliabadi, N., & Habibi, M. (2023) · Virology Journal · doi:10.1186/s12985-023-02156-2 · Cited by 7

Advanced Facial Mask Using Roll‐to‐Roll Processed Superhydrophobic Vertically Aligned Carbon Nanotubes for Enhanced Antiviral Effects and Reusability

Lee, I. H., Woo, C. Y., Seo, Y., Lee, S., Kim, H., Lee, H. W., & Jeon, I. (2025) · SusMat · doi:10.1002/sus2.70001 · Cited by 8

Case Report: Infection With SARS-CoV-2 in the Presence of High Levels of Vaccine-Induced Neutralizing Antibody Responses

Schulte, B., Marx, B., Korencak, M., Emmert, D., Aldabbagh, S., Eis-Hübinger, A., & Streeck, H. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.704719 · Cited by 7

Pediatric Intensive Care Hybrid-Style Clinical Round During COVID-19 Pandemic: A Pilot Study

Temsah, M.-H. A., Alhaboob, A. A. N., Abouammoh, N. A., Al-Eyadhy, A. A., Aljamaan, F., Alsohime, F., Alabdulhafid, M., Ashry, A., Bukhari, A., ElTahir, O., et al. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2021.720203 · Cited by 9

Papel protector de las actuales vacunas para las variantes del virus SARS-CoV-2 y la COVID persistente

Marco, J., Pasquín, M. J. Á., Martín, S. M., & Miranda, A. P. J. (2022) · Formacion Medica Continuada En Atencion Primaria · doi:10.1016/j.fmc.2021.10.001 · Cited by 6

A Recombinant Subunit Vaccine Induces a Potent, Broadly Neutralizing, and Durable Antibody Response in Macaques against the SARS-CoV-2 P.1 (Gamma) Variant

To, A., Wong, T. A. S., Lieberman, M. M., Thompson, K. S., Ball, A. H., Pessaint, L., Greenhouse, J. J., Daham, N., Cook, A., Narvaez, B., et al. (2022) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00600 · Cited by 8

A recombinant subunit vaccine candidate produced in plants elicits neutralizing antibodies against SARS-CoV-2 variants in macaques

Khorattanakulchai, N., Srisutthisamphan, K., Shanmugaraj, B., Manopwisedjaroen, S., Rattanapisit, K., Panapitakkul, C., Kemthong, T., Suttisan, N., Malaivijitnond, S., Thitithanyanont, A., et al. (2022) · Frontiers in Plant Science · doi:10.3389/fpls.2022.901978 · Cited by 8

An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response

Chen, L., Zhang, H., Li, M., Wu, B., Zhang, Z., & Gong, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1005321 · Cited by 8

Advanced Vaccine Design Strategies against SARS-CoV-2 and Emerging Variants

Zhang, J., Xia, Y., Liu, X., & Liu, G. (2023) · Bioengineering · doi:10.3390/bioengineering10020148 · Cited by 8

An Overview of Current Accomplishments and Gaps of COVID-19 Vaccine Platforms and Considerations for Next Generation Vaccines

Kale, A., Gaur, A., Menon, I., Chirmule, N. B., Bagwe, P., Jawa, R., Vijayanand, S., Patil, S., Suresh, S., & Jawa, V. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.01.019 · Cited by 8

Vaccination coverage and breakthrough infections of COVID-19 during the second wave among staff of selected medical institutions in India

Rahi, M., Yadav, C. P., Ahmad, S. S., Nitika, Das, P., Sharma, S., Baharia, R. K., Bhattacharya, D., Deshmukh, P. R., Dhatrak, A. A., et al. (2023) · PLOS Global Public Health · doi:10.1371/journal.pgph.0000946 · Cited by 8

A third COVID-19 vaccine shot markedly boosts neutralizing antibody potency and breadthPreprint

Iketani, S., Liu, L., Nair, M. S., Mohri, H., Wang, M., Huang, Y., & Ho, D. D. (2021) · medRxiv · doi:10.1101/2021.08.11.21261670 · Cited by 8

Demographic characteristics of SARS-CoV-2 B.1.617.2 (Delta) variant infections in Indian populationPreprint

Kumar, A., Asghar, A., Raza, K., Narayan, R. K., Jha, R. K., Satyam, A., Kumar, G., Dwivedi, P., Sahni, C., Kumari, C., et al. (2021) · medRxiv · doi:10.1101/2021.09.23.21263948 · Cited by 8

Epidemiological Characteristics of Sporadic Nosocomial COVID-19 Infections From June 2020 to June 2021 in China: An Overview of Vaccine Breakthrough Infection Events

He, Z., Xiang, H., Manyande, A., Xu, W., Li, F., & Xiang, B. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.736060 · Cited by 7

Surveillance genome sequencing reveals multiple SARS‐CoV‐2 variants circulating in central Texas, USA, with a predominance of delta variant and review of vaccine breakthrough cases

Mutnal, M. B., Johnson, S., Mohamed, N., Abddelgader, R., Morales, L., Volz, M., Walker, K., Arroliga, A. C., & Rao, A. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27373 · Cited by 7

Clinical and Genomic Characterization of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Infections in mRNA Vaccinated Health Care Personnel in New York City

Robilotti, E. V., Whiting, K. A., Bianchi, A. L., Poon, C., Guest, R., McMillen, T. A., Jani, K., Solovyov, A., Kelson, S., Browne, K., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab886 · Cited by 7

The short-term effectiveness of coronavirus disease 2019 (COVID-19) vaccines among healthcare workers: a systematic literature review and meta-analysis

Marra, A. R., Kobayashi, T., Suzuki, H., Alsuhaibani, M., Tofaneto, B. M., Bariani, L. M., Auler, M. D. A., Salinas, J. L., Edmond, M. B., Pinho, J. R. R., et al. (2021) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2021.195 · Cited by 7

Vaccination and Government Stringent Control as Effective Strategies in Preventing SARS-CoV-2 Infections: A Global Perspective

Yang, P., Yang, Z., Zhao, C., Li, X., Shao, Z., Liu, K., & Shang, L. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.903511 · Cited by 7

SARS-CoV-2 Variants of Concern and Variations within Their Genome Architecture: Does Nucleotide Distribution and Mutation Rate Alter the Functionality and Evolution of the Virus?

Ravi, V., Swaminathan, A., Yadav, S. K., Arya, H., & Pandey, R. (2022) · Viruses · doi:10.3390/v14112499 · Cited by 7

Molnupiravir Use and 30-Day Hospitalizations or Death in a Previously Uninfected Nonhospitalized High-risk Population With COVID-19

Butt, A. A., Peng, Y., Shaikh, O. S., Omer, S. B., Mayr, F., & Talisa, V. B. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad195 · Cited by 7

Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison

Kroidl, I., Winter, S., Rubio‐Acero, R., Bakuli, A., Geldmacher, C., Eser, T. M., Deák, F., Horn, S., Zielke, A., Ahmed, M. I. M., et al. (2023) · Virology Journal · doi:10.1186/s12985-023-02167-z · Cited by 7

Breakthrough infections by SARS-CoV-2 variants boost cross-reactive hybrid immune responses in mRNA-vaccinated Golden Syrian hamsters

Diego, J. G.-B., Singh, G., Jangra, S., Handrejk, K., Laporte, M., Chang, L. A., Zahed, S. S. E., Pache, L., Chang, M. W., Warang, P., et al. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1011805 · Cited by 8

Decline in Sars‐CoV‐2 antibodies over 6‐month follow‐up in obstetrical healthcare workers

Kiefer, M. K., Allen, K. D., Russo, J. R., Ma’ayeh, M., Gee, S. E., Kniss, D. A., Cackovic, M., Costantine, M. M., & Rood, K. M. (2021) · American Journal of Reproductive Immunology · doi:10.1111/aji.13490 · Cited by 6

Study of immunogenicity, safety and efficacy of covishield vaccine among health care workers in a tertiary cardiac care centre

Mahadevaiah, A., Doddamadaiah, C., Sadananda, K., & Nanjappa, M. C. (2022) · Indian Journal of Medical Microbiology · doi:10.1016/j.ijmmb.2022.03.003 · Cited by 9

Abiotic Synthetic Antibody Inhibitor with Broad-Spectrum Neutralization and Antiviral Efficacy against Escaping SARS-CoV-2 Variants

Li, B., Zhao, Y., Wu, X., Wu, H., Tang, W., Yu, X., Mou, J., Tan, W., Jin, M., Li, W., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c02050 · Cited by 7

The Potential Protective Role of GS-441524, a Metabolite of the Prodrug Remdesivir, in Vaccine Breakthrough SARS-CoV-2 Infections

Zhu, J., Li, Y., Liang, J., Mubareka, S., Slutsky, A. S., & Zhang, H. (2022) · Intensive Care Research · doi:10.1007/s44231-022-00021-4 · Cited by 6

A third SARS-CoV-2 mRNA vaccine dose in people receiving hemodialysis overcomes B cell defects but elicits a skewed CD4+ T cell profile

Sannier, G., Nicolas, A., Dubé, M., Marchitto, L., Nayrac, M., Tastet, O., Chatterjee, D., Tauzin, A., Lima-Barbosa, R., Laporte, M., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100955 · Cited by 6

SARS-CoV-2 spike-based virus-like particles incorporate influenza H1/N1 antigens and induce dual immunity in mice

Sanchez-Martinez, Z. V., Alpuche‐Lazcano, S. P., Stuible, M., Akache, B., Renner, T. M., Deschatelets, L., Dudani, R., Harrison, B. A., McCluskie, M. J., Hrapovic, S., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126463 · Cited by 8

Personalized Therapy: Can it Tame the COVID-19 Monster?

Arish, M., & Naz, F. (2021) · Personalized Medicine · doi:10.2217/pme-2021-0077 · Cited by 6

In-depth Characterization of Vaccine Breakthrough Infections With SARS-CoV-2 Among Health Care Workers in a Dutch Academic Medical Center

Rümke, L. W., Groenveld, F. C., van Os, Y. M. G., Praest, P., Tanja, A. A. N., de Jong, D. C. M., Symons, J., Schuurman, R., Reinders, T., Hofstra, L. M., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab553 · Cited by 6

Setting-Up a Rapid SARS-CoV-2 Genome Assessment by Next-Generation Sequencing in an Academic Hospital Center (LPCE, Louis Pasteur Hospital, Nice, France)

Hofman, P. M., Bordone, O., Chamorey, E., Benzaquen, J., Schiappa, R., Lespinet‐Fabre, V., Lantéri, E., Brest, P., Mograbi, B., Maniel, C., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.730577 · Cited by 7

A Comprehensive Investigation Regarding the Differentiation of the Procurable COVID-19 Vaccines

Banerjee, S., Banerjee, D., Singh, A., & Saharan, V. A. (2022) · AAPS PharmSciTech · doi:10.1208/s12249-022-02247-3 · Cited by 6

Comparison of the Clinical and Laboratory Findings and Outcomes of Hospitalized COVID-19 Patients Who Were Either Fully Vaccinated with Coronavac or Not: An Analytical, Cross Sectional Study

Yavuz, S. Ş., Tunçer, G., Aydın, Ö. A., Aydın, M., Pehlıvanoglu, F., Tok, Y., Meşe, S., Gündüz, A., Geyiktepe-Güçlü, C., Özdoğan, İ., et al. (2022) · Vaccines · doi:10.3390/vaccines10050733 · Cited by 7

Saliva molecular testing bypassing RNA extraction is suitable for monitoring and diagnosing SARS-CoV-2 infection in children

Alenquer, M., Silva, T. M., Akpogheneta, O., Ferreira, F., Vale-Costa, S., Medina-Lopes, M., Batista, F., Garcia, A. M., Barreto, V. M., Paulino, C., et al. (2021) · medRxiv · doi:10.1371/journal.pone.0268388 · Cited by 8

Combining predictive models with future change scenarios can produce credible forecasts of COVID-19 futures

Newcomb, K., Bilal, S., & Michael, E. (2022) · PLoS ONE · doi:10.1371/journal.pone.0277521 · Cited by 6

SARS-CoV-2 infection outcomes associated with the Delta variant: A prospective cohort study

Gallant, M., Rioux‐Perreault, C., Lemaire‐Paquette, S., & Piché, A. (2022) · Journal of the Association of Medical Microbiology and Infectious Disease Canada · doi:10.3138/jammi-2022-0022 · Cited by 5

Prevalence and characteristics of COVID-19 vaccine breakthrough infection in Upper Egypt

Hussein, A. A. R. M., Hashem, M. K., Azizeldine, M. G., & Shaddad, A. M. (2023) · Egyptian Journal of Bronchology · doi:10.1186/s43168-023-00196-4 · Cited by 8

Potential Benefits of Expanded COVID-19 Surveillance in the US

Holtgräve, D. R., Vermund, S. H., & Wen, L. S. (2021) · JAMA · doi:10.1001/jama.2021.11211 · Cited by 6

Understanding the devastating second wave of COVID ‐19 pandemic in India

Chinnaswamy, S. (2021) · American Journal of Human Biology · doi:10.1002/ajhb.23671 · Cited by 5

SARS-CoV-2 infection despite high levels of vaccine-induced anti-Receptor-Binding-Domain antibodies: a study on 1110 health-care professionals from a northern Italian university hospital

Ferrari, D., Clementi, N., Mancini, N., & Locatelli, M. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.10.010 · Cited by 6

Dominance of Alpha and Iota variants in SARS-CoV-2 vaccine breakthrough infections in New York City

Duerr, R., Dimartino, D., Marier, C., Zappile, P., Wang, G., Lighter, J., Elbel, B. D., Troxel, A. B., & Heguy, A. (2021) · Journal of Clinical Investigation · doi:10.1172/jci152702 · Cited by 53

Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals

Kustin, T., Harel, N., Finkel, U., Perchik, S., Harari, S., Tahor, M., Caspi, I., Levy, R., Leshchinsky, M., Ken Dror, S., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01413-7 · Cited by 373

Low‐frequency variants in mildly symptomatic vaccine breakthrough infections presents a doubled‐edged sword

Magalis, B. R., Mavian, C. N., Tagliamonte, M. S., Rich, S. N., Cash, M. N., Riva, A., Loeb, J. C., Norris, M. H., Amador, D. M., Zhang, Y., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27726 · Cited by 9

In-depth Characterization of Vaccine Breakthrough Infections With SARS-CoV-2 Among Health Care Workers in a Dutch Academic Medical Center

Rümke, L. W., Groenveld, F. C., van Os, Y. M. G., Praest, P., Tanja, A. A. N., de Jong, D. C. M., Symons, J., Schuurman, R., Reinders, T., Hofstra, L. M., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab553 · Cited by 6

Rate and risk factors for breakthrough SARS-CoV-2 infection after vaccination

Butt, A. A., Khan, T., Peng, Y., Shaikh, O. S., Omer, S. B., & Mayr, F. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.05.021 · Cited by 53